ArticleMedicine international
Spontaneous regression of a growth hormone-secreting pituitary adenoma following thyroidectomy for toxic multinodular goiter with superior vena cava obstruction: Report of a rare case.
Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is most commonly caused by a growth hormone (GH)-secreting pituitary adenoma; the spontaneous regression of such tumors is exceedingly rare. The present study reports the case of a 51-year-old male patient with long-standing acromegaly who developed a toxic multinodular goiter complicated by superior vena cava obstruction (SVCO). An initial evaluation revealed a pituitary macroadenoma measuring 19x17x16 mm, with elevated GH and insulin-like growth factor-1 (IGF-1) levels, consistent with acromegaly. The patient was treated with a somatostatin analog and metformin for glycemic control, followed by carbimazole in preparation for thyroidectomy. He subsequently underwent urgent total thyroidectomy for compressive symptoms due to SVCO. Post-thyroidectomy, he experienced marked clinical improvement, including the resolution of dyspnea, improved sleep quality, enhanced mood and partial regression of acromegaly symptoms. Biochemically, IGF-1 normalized within 6 months of total thyroidectomy, and an MRI demonstrated the progressive shrinkage of the pituitary adenoma, reducing to 8x6x5.5 mm at 1 year without neurosurgical intervention. Possible mechanisms for regression include perioperative pituitary apoplexy, spontaneous ischemia, or altered vascular dynamics following thyroidectomy. The present case report highlights the importance of reassessing pituitary adenomas following the treatment of coexisting endocrine or compressive disorders and suggests a potential role of vascular factors in pituitary tumor regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.